Literature DB >> 35299831

The impact of surveillance and other factors on detection of emergent and circulating vaccine derived polioviruses.

Megan Auzenbergs1, Holly Fountain1, Grace Macklin1,2, Hil Lyons3, Kathleen M O'Reilly1.   

Abstract

Background: Circulating vaccine derived poliovirus (cVDPV) outbreaks remain a threat to polio eradication. To reduce cases of polio from cVDPV of serotype 2, the serotype 2 component of the vaccine has been removed from the global vaccine supply, but outbreaks of cVDPV2 have continued. The objective of this work is to understand the factors associated with later detection in order to improve detection of these unwanted events.
Methods: The number of nucleotide differences between each cVDPV outbreak and the oral polio vaccine (OPV) strain was used to approximate the time from emergence to detection. Only independent emergences were included in the analysis. Variables such as serotype, surveillance quality, and World Health Organization (WHO) region were tested in a negative binomial regression model to ascertain whether these variables were associated with higher nucleotide differences upon detection.
Results: In total, 74 outbreaks were analysed from 24 countries between 2004-2019. For serotype 1 (n=10), the median time from seeding until outbreak detection was 284 (95% uncertainty interval (UI) 284-2008) days, for serotype 2 (n=59), 276 (95% UI 172-765) days, and for serotype 3 (n=5), 472 (95% UI 392-603) days. Significant improvement in the time to detection was found with increasing surveillance of non-polio acute flaccid paralysis (AFP) and adequate stool collection. Conclusions: cVDPVs remain a risk; all WHO regions have reported at least one VDPV outbreak since the first outbreak in 2000 and outbreak response campaigns using monovalent OPV type 2 risk seeding future outbreaks. Maintaining surveillance for poliomyelitis after local elimination is essential to quickly respond to both emergence of VDPVs and potential importations as low-quality AFP surveillance causes outbreaks to continue undetected. Considerable variation in the time between emergence and detection of VDPVs were apparent, and other than surveillance quality and inclusion of environmental surveillance, the reasons for this remain unclear. Copyright:
© 2022 Auzenbergs M et al.

Entities:  

Keywords:  OPV; cVDPVs; eradication; polio; vaccination

Year:  2022        PMID: 35299831      PMCID: PMC8913522.2          DOI: 10.12688/gatesopenres.13272.2

Source DB:  PubMed          Journal:  Gates Open Res        ISSN: 2572-4754


  30 in total

Review 1.  Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative.

Authors:  P E Fine; I A Carneiro
Journal:  Am J Epidemiol       Date:  1999-11-15       Impact factor: 4.897

2.  Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children.

Authors:  Elena Samoilovich; Merja Roivainen; L P Titov; Tapani Hovi
Journal:  J Med Virol       Date:  2003-10       Impact factor: 2.327

3.  Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range.

Authors:  Jaume Jorba; Ray Campagnoli; Lina De; Olen Kew
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

4.  Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated?

Authors:  M Eichner; K Dietz
Journal:  Am J Epidemiol       Date:  1996-04-15       Impact factor: 4.897

5.  The show is not over - wild-type polio in Malawi is a wake-up call and an opportunity for elimination efforts.

Authors:  Kerrigan McCarthy; Wayne Howard; Mukhlid Yousif; Shelina Moonsamy; Melinda Suchard
Journal:  Int J Infect Dis       Date:  2022-03-05       Impact factor: 3.623

6.  The role of supplementary environmental surveillance to complement acute flaccid paralysis surveillance for wild poliovirus in Pakistan - 2011-2013.

Authors:  Tori L Cowger; Cara C Burns; Salmaan Sharif; Howard E Gary; Jane Iber; Elizabeth Henderson; Farzana Malik; Syed Sohail Zahoor Zaidi; Shahzad Shaukat; Lubna Rehman; Mark A Pallansch; Walter A Orenstein
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

7.  Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.

Authors:  Michael Famulare; Christian Selinger; Kevin A McCarthy; Philip A Eckhoff; Guillaume Chabot-Couture
Journal:  PLoS Biol       Date:  2018-04-27       Impact factor: 8.029

Review 8.  Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.

Authors:  Edward Pk Parker; Natalie A Molodecky; Margarita Pons-Salort; Kathleen M O'Reilly; Nicholas C Grassly
Journal:  Expert Rev Vaccines       Date:  2015-07-09       Impact factor: 5.217

9.  New analytic approaches for analyzing and presenting polio surveillance data to supplement standard performance indicators.

Authors:  Kristin VanderEnde; Arend Voorman; Sara Khan; Abhijeet Anand; Cynthia J Snider; Ajay Goel; Steve Wassilak
Journal:  Vaccine X       Date:  2020-03-21

Review 10.  Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Expert Rev Vaccines       Date:  2020-08-01       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.